BCAX
Bicara Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.98 / 10
Netural
Fund flow is strong (7.96/10) with positive inflows across all investor sizes. Analyst coverage is limited: two Buy ratings, no Strong Buys, and zero historical win rates, while price has fallen 6.55% and market expectations are pessimistic.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-13
InstitutionWedbush
Times predicted1
Historical Win Rate0.0%
Is money flowing into or out of BCAX?
- BCAX holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.98/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
